| Trial ID # | NCT00989651; GOG-9923 |
| Phase | I |
| Drug Class | DNA Damage Repair Pathway Inhibitors: PARP |
| Drug Name | Veliparib |
| Alternate Drug Names | ABT-888 |
| Drugs in Trial | Carboplatin, Cisplatin, Paclitaxel, Veliparib, Bevacizumab |
| Eligible Participant | Newly diagnosed stage II-IV ovarian cancer |
| Patients Enrolled | 424 stage II-IV ovarian cancer (73.6% stage III) |
| Therapy Setting | First-line |
| Study Design | Open-Label, Non-randomized |
| Endpoints | PFS, OS, evaluated per RECIST |
| Efficacy | IV: IV CarboPt+Pac+Bev every 21 days w/ Bev maint (n=173) IV Vel cont vs IV Vel int vs weekly IV Vel cont vs weekly IV Vel int vs IP Vel cont vs IP Vel int: |
| Clinically Significant Adverse Events | IV vs weekly IV vs IP: |
| Conclusion | Patients receiving IP cisplatin + IV/IP paclitaxel show promising PFS and OS when compared to patients receiving IV carboplatin+paclitaxel, however differences may be reflective of selection bias toward patients enrolled on the IP chemotherapy arm |
| Reference | Washington CR et al. Outcomes based on treatment regimen in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer receiving intravenous or intraperitoneal platinum-based chemotherapy in combination with veliparib and bevacizumab. SGO (2020) abstract 27 Gillen J et al. Tolerability and adverse events experienced by women with ovarian cancer treated with intravenous or intraperitoneal chemotherapy plus veliparib and bevacizumab based on BRCA status. SGO (2020) abstract 26 |